发明申请
- 专利标题： SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY
- 专利标题（中）： 免疫应答的抗IL-6受体抗体
-
申请号： US13290366申请日： 2011-11-07
-
公开(公告)号： US20120301460A1公开(公告)日： 2012-11-29
- 发明人: Min Bao , Olivier Alfred Harari , Angelika M. Jahreis , Johannes F. Schmidt , Xiaoping Zhang
- 申请人： Min Bao , Olivier Alfred Harari , Angelika M. Jahreis , Johannes F. Schmidt , Xiaoping Zhang
- 申请人地址： US NJ Nutley US CA South San Francisco
- 专利权人： Hoffmann-La Roche, Inc.,Genentech, Inc.
- 当前专利权人： Hoffmann-La Roche, Inc.,Genentech, Inc.
- 当前专利权人地址： US NJ Nutley US CA South San Francisco
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; A61P19/02 ; A61P29/00
摘要：
The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
公开/授权文献
- US08580264B2 Subcutaneously administered anti-IL-6 receptor antibody 公开/授权日：2013-11-12
信息查询
